TNSN06226A1 - Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases - Google Patents

Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Info

Publication number
TNSN06226A1
TNSN06226A1 TNP2006000226A TNSN06226A TNSN06226A1 TN SN06226 A1 TNSN06226 A1 TN SN06226A1 TN P2006000226 A TNP2006000226 A TN P2006000226A TN SN06226 A TNSN06226 A TN SN06226A TN SN06226 A1 TNSN06226 A1 TN SN06226A1
Authority
TN
Tunisia
Prior art keywords
pyrimidin
pyrazolo
treatment
protein kinase
dependent diseases
Prior art date
Application number
TNP2006000226A
Other languages
French (fr)
Inventor
Patricia Imbach
Keiichi Masuya
Georg Martiny-Baron
Guido Bold
Pascal Furet
Joseph Schoepfer
Andreas Floersheimer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06226(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN06226A1 publication Critical patent/TNSN06226A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.
TNP2006000226A 2004-01-22 2006-07-21 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases TNSN06226A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53822004P 2004-01-22 2004-01-22
PCT/EP2005/000602 WO2005070431A1 (en) 2004-01-22 2005-01-21 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Publications (1)

Publication Number Publication Date
TNSN06226A1 true TNSN06226A1 (en) 2007-12-03

Family

ID=34807167

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000226A TNSN06226A1 (en) 2004-01-22 2006-07-21 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Country Status (17)

Country Link
EP (1) EP1708710A1 (en)
JP (1) JP2007519662A (en)
KR (1) KR20070009546A (en)
CN (1) CN1909908A (en)
AR (1) AR049769A1 (en)
AU (1) AU2005205915B2 (en)
BR (1) BRPI0507071A (en)
CA (1) CA2552885A1 (en)
EC (1) ECSP066718A (en)
IL (1) IL176737A0 (en)
MA (1) MA28400B1 (en)
NO (1) NO20063758L (en)
PE (1) PE20051089A1 (en)
RU (1) RU2006130003A (en)
TN (1) TNSN06226A1 (en)
TW (1) TW200528103A (en)
WO (1) WO2005070431A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
MX2008008152A (en) 2005-12-23 2008-09-12 Ariad Pharma Inc Bicyclic heteroaryl compounds.
MX2008011430A (en) * 2006-03-08 2008-09-18 Novartis Ag Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders.
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
GB0606805D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic compounds
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
BRPI0717134A2 (en) * 2006-09-28 2013-10-15 Novartis Ag PIRAZOL [1,5-A] PYRIMIDINE DERIVATIVES AND THEIR USE OF THERAPEUTIC
ATE502943T1 (en) 2006-09-29 2011-04-15 Novartis Ag PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
EP1918291A1 (en) * 2006-10-30 2008-05-07 Novartis AG 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
MX2009013336A (en) * 2007-06-07 2010-01-20 Schering Corp Synthesis of substituted-3-aminopyrazoles.
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
UY33227A (en) * 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
RU2562833C2 (en) * 2010-08-09 2015-09-10 НБ Хелс Лаборатори Ко. Лтд. Inhibitor of casein kinase 1 delta and casein kinase 1 ?
WO2012023143A1 (en) 2010-08-19 2012-02-23 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2013077579A1 (en) * 2011-11-25 2013-05-30 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing and treating ophthalmic disorders
CN105906630B (en) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN106588893A (en) * 2016-12-01 2017-04-26 北京万全德众医药生物技术有限公司 Preparation of vilazodone double oxide
JP6888101B2 (en) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
KR20200116481A (en) * 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 GCN2 inhibitors and uses thereof
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
CN109836428A (en) * 2019-02-27 2019-06-04 华东师范大学 Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
JOP20220125A1 (en) 2019-11-25 2023-01-30 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
WO2023154282A1 (en) * 2022-02-08 2023-08-17 Theras, Inc. Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
CN114751910B (en) * 2022-05-17 2023-02-24 重庆文理学院 Compound capable of inducing cell megalophage death and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (en) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM
KR100191774B1 (en) * 1991-04-22 1999-06-15 오스카 아끼히꼬 Pyrazolo(1,5-alpha)pyrimidine derivatives and anti-inflammatory agent containing them
JP3163413B2 (en) * 1994-06-21 2001-05-08 株式会社大塚製薬工場 Painkillers
CN1046730C (en) * 1994-06-21 1999-11-24 株式会社大塚制药工场 Pyrazolo [1,5-a] pyrimidine derivative
WO1998010590A1 (en) * 1996-09-02 1998-03-12 Sony Corporation Device and method for transmitting video signal
MXPA05002570A (en) * 2002-09-04 2005-09-08 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors.
US7084271B2 (en) * 2002-09-04 2006-08-01 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
MA28400B1 (en) 2007-01-02
IL176737A0 (en) 2006-10-31
AU2005205915B2 (en) 2009-05-21
RU2006130003A (en) 2008-04-10
ECSP066718A (en) 2006-10-31
AU2005205915A1 (en) 2005-08-04
PE20051089A1 (en) 2006-01-25
JP2007519662A (en) 2007-07-19
BRPI0507071A (en) 2007-06-19
WO2005070431A1 (en) 2005-08-04
CN1909908A (en) 2007-02-07
NO20063758L (en) 2006-10-23
EP1708710A1 (en) 2006-10-11
TW200528103A (en) 2005-09-01
KR20070009546A (en) 2007-01-18
CA2552885A1 (en) 2005-08-04
AR049769A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
GB0211649D0 (en) Organic compounds
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
PL1687305T3 (en) 1h-imidazoquinoline derivatives as protein kinase inhibitors
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GB0330043D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BR0315988A (en) Amino-substituted dihydropyrimidate [4,5-d] pyrimidinone derivatives, their production and use as pharmaceutical agents
MX2007005644A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors.
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
CA2555262C (en) 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2006110298A3 (en) 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
PL2004653T3 (en) 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
MXPA05009719A (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
MXPA05012826A (en) COMPOUNDS USEFUL IN THE THERAPY OF ALZHEIMERaCOES DISEASE AND FORMULATIONS CONTAINING THEM.
IL203601A (en) 6-halo-7-(optionally substituted amino)-pyrazolo[1,5-a] pyrimidine derivatives and their use for the preparation of medicaments